Prostate Cancer - Results from #1700

Adjuvant and salvage radiotherapy after neoadjuvant therapy and radical prostatectomy for high-risk localized prostate cancer. December 4, 2023

UBE2J1 is the E2 ubiquitin-conjugating enzyme regulating androgen receptor degradation and antiandrogen resistance. December 4, 2023

Semaphorin 3C promotes de novo steroidogenesis in prostate cancer cells. December 4, 2023

First Patient with Metastatic Prostate Cancer to Receive 2 Doses of Cu-67 SAR-bisPSMA Achieves Undetectable PSA Level December 1, 2023

Registrational Phase III CLARIFY Trial in Prostate Cancer Commences December 1, 2023

Clinical outcomes for men with positive surgical margins after radical prostatectomy-results from the South Australian Prostate Cancer Clinical Outcomes Collaborative community-based registry. December 1, 2023

Stereotactic body radiotherapy with CyberKnife® System for low- and intermediate-risk prostate cancer: clinical outcomes and toxicities of CyPro Trial. December 1, 2023

Glucocorticoid receptor (GR) activation is associated with increased cAMP/PKA signaling in castrate-resistant prostate cancer. December 1, 2023

Circulating Tumour DNA Biomarkers Associated with Outcomes in Metastatic Prostate Cancer Treated with Lutetium-177-PSMA-617. December 1, 2023

CT-based online adaptive radiotherapy improves target coverage and organ at risk (OAR) avoidance in stereotactic body radiation therapy (SBRT) for prostate cancer. December 1, 2023

Social Drivers of Cancer Risk and Outcomes Among African American Men. December 1, 2023

Heterogeneity of prostate-specific membrane antigen (PSMA) and PSMA-ligand uptake detection combining autoradiography and postoperative pathology in primary prostate cancer. December 1, 2023

POSTER: Phase 1/2 Trial of Oral EPI-7386 (masofaniten) in Combination with Enzalutamide (Enz) Compared with Enz Alone in Subjects mCRPC: Current Phase 1 (P1) Results November 30, 2023

Comparison of 18F-based PSMA radiotracers with [68Ga]Ga-PSMA-11 in PET/CT imaging of prostate cancer-a systematic review and meta-analysis. November 30, 2023

Imaging tumor lactate is feasible for identifying intermediate-risk prostate cancer patients with postsurgical biochemical recurrence. November 30, 2023

Actigraphy-derived measures of sleep and risk of prostate cancer in the UK Biobank. November 30, 2023

Intratumoral androgen biosynthesis associated with 3β-hydroxysteroid dehydrogenase 1 promotes resistance to radiotherapy in prostate cancer. November 30, 2023

Differential Impact of SPOP Mutation in Prostate and Endometrial Cancers. November 30, 2023

Clarity's Theranostic Prostate Cancer Trial Progresses at the Highest Dose Level Cohort November 29, 2023

Can We Predict Skeletal Lesion on Bone Scan Based on Quantitative PSMA PET/CT Features? November 29, 2023

Page 86 of 1435